An interventional study of Stent Placement Timing - Early and Stent Placement Timing - Late in Coronary Occlusion, Coronary Stenosis and Coronary Restenosis, sponsored by Saint Luke's Health System. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.
Sponsored by Saint Luke's Health System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Coronary Occlusion with a site in United States — 1 open to participants now, 1 under way, 1 of them phase 3. Coronary Occlusion · United States.
Among the 13 studies in Coronary Occlusion with a site in United States, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 4 with no phase, and was the 11th registered.
71 studies on the registry are indexed under Coronary Occlusion; 11 are open to participants now.
Browse Coronary Occlusion studies →1 of the 13 studies in Coronary Occlusion with a site in United States is open now. Recruiting first, the newest first:
ReFlow Medical, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Coronary Occlusion studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2021.
This study's enrollment of 150 is above the median of 135 across 45 interventional studies indexed under Coronary Occlusion.
Median enrollment 153 across the 10 interventional studies, 80 across the 3 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Saint Luke's Health System is the lead sponsor of 35 studies on the registry; 3 are open to participants now.
Saint Luke's Health System has 1 study filed under Coronary Occlusion — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Coronary Occlusion with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
STAR is a minimal-risk pragmatic clinical trial of patients admitted for a CTO-PCI procedure. The overall objective of the STAR Study is to address the current gaps in knowledge regarding use of STAR during CTO-PCI, as a prospective, multi-center study of 150 participants with randomization of timing of staged PCI. Five sites will be selected to participate in STAR from a national network of highly experienced CTO-PCI centers across the United States.
To date, there have been no studies that prospectively and systemically evaluated the efficacy and safety of STAR with deferred stenting and described the frequency of its use in the hybrid approach. The aim of this study is to address these current gaps in knowledge, including the frequency of use of STAR by experienced operators, the safety of its use, optimal timing of staged stenting and health status change associated with this procedure. This prospective study will enroll 150 patients undergoing elective PCI of native CTO utilizing the STAR technique and will subsequently randomize patients in a 1:1 fashion to early (5-7 weeks) and later (12-14 weeks) timing of subsequent stenting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Unable to participate in telephone follow-up
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stent placement 5-7 weeks post-STAR procedure
Other: Stent Placement Timing - Early
Stent placement 12-14 weeks post-STAR procedure
Other: Stent Placement Timing - Late
Stent placement 5-7 weeks after STAR procedure
Stent placement 12-14 weeks after STAR procedure
Staged Procedure Success
success of the staged stenting procedure will be core lab adjudicated and defined as TIMI 3 flow, no major side branch loss, and residual stenosis \<30%
Time frame: 14 weeks
Vessel patency at time of staged stenting procedure
number of distal branches, and the antegrade TIMI flow through the vessel, assessed by core-lab analysis
Time frame: 14 weeks
Plan to share: No
Ran from Nov 2021 to primary completion in Aug 2025, 44 months.
Of 16 interventional studies with no phase under Coronary Occlusion, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 44 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint Luke's Health System